Hubbry Logo
Caco-2Caco-2Main
Open search
Caco-2
Community hub
Caco-2
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Caco-2
Caco-2
Caco-2
View on Wikipedia
from Wikipedia
Phase contrast micrograph of confluent Caco-2 cells

Caco-2 (from Cancer coli, "colon cancer") is an immortalized cell line of human colorectal adenocarcinoma cells. It is primarily used as a model of the intestinal epithelial barrier.[1] In culture, Caco-2 cells spontaneously differentiate into a heterogeneous mixture of intestinal epithelial cells.[1] It was developed in 1977 by Jorgen Fogh at the Sloan-Kettering Institute for Cancer Research.[2]

History

[edit]

The line was developed in 1977 by Jorgen Fogh at the Sloan-Kettering Institute for Cancer Research.[2] The research application of Caco-2 cells was developed during the 1980s by Alain Zweibaum group at INSERM, France as well as Ismael Hidalgo, at the Borchardt laboratory, University of Kansas and Tom Rauband at the Upjohn Company. The first publication of the discovery of the spontaneous enterocyte like differentiation was published by Alain Zweibaum group in 1983.[3]

Characteristics

[edit]

Although derived from a colon (large intestine) carcinoma, when cultured under specific conditions the cells become differentiated and polarized such that their phenotype, morphologically and functionally, resembles the enterocytes lining the small intestine.[3][4] Polarized Caco-2 cells express tight junctions, microvilli, and a number of enzymes and transporters that are characteristic of such enterocytes: peptidases, esterases, P-glycoprotein, uptake transporters for amino acids, bile acids, carboxylic acids, etc.

Research applications

[edit]

Microscopically, Caco-2 cell cultures show obvious heterogeneity likely reflecting the complex mixture of cells found in the epithelial lining of the large and small intestine i.e. enterocytes, enteroendocrine cells, goblet cells, transit amplifying cells, paneth cells and intestinal stem cells.[5] Over time, the characteristics of the cells used in different laboratories have diverged, introducing inter-laboratory variation.[6] Despite such heterogeneity, Caco-2 cells are used in cell invasion studies, viral transfection research, and lipid transport.[7]

Caco-2 cells may be used as a confluent monolayer on a cell culture insert filter (e.g., Transwell). In this format, Caco-2 cells form a polarized epithelial cell monolayer that provides a physical and biochemical barrier to the passage of ions and small molecules.[4][8] The Caco-2 monolayer can be used as an in vitro model of the human small intestinal mucosa to predict the absorption of orally administered drugs. Kits, such as the CacoReady, have been developed to simplify this procedure.[9] A correlation between the in vitro apparent permeability across Caco-2 monolayers and the in vivo fraction absorbed has been reported.[10] Transwell diagram

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Caco-2

View on Grokipedia
from Grokipedia
The Caco-2 cell line is an immortalized human epithelial cell line derived from a colorectal tumor in the colon of a 72-year-old Caucasian male patient, originally established in 1977 at the Sloan-Kettering Institute for Cancer Research using techniques. When cultured to , Caco-2 cells spontaneously differentiate into polarized monolayers resembling small intestinal absorptive enterocytes, complete with microvilli, brush borders, tight junctions, and dome formation indicative of ion transport. This differentiation process typically requires 15–21 days post-confluence on permeable supports, such as Transwell inserts with 0.4 μm pore size filters, resulting in high transepithelial electrical resistance (TEER) values often exceeding 300 Ω·cm², which confirms the formation of a functional barrier. Caco-2 cells express a range of intestinal enzymes (e.g., sucrase-isomaltase, , ) and transporters (e.g., , peptide transporters), though they lack significant activity and represent primarily enterocytic cells without the heterogeneity of other intestinal cell types like goblet or Paneth cells. The cell line is heterogeneous, with subpopulations exhibiting varying differentiation potential, and its properties can be influenced by passage number, culture conditions, and subclone selection. Caco-2 monolayers are extensively employed in pharmaceutical research as a predictive model for oral absorption, , and , correlating well (r > 0.8) with human bioavailability data for passively transported compounds. They facilitate bidirectional studies to distinguish apical-to-basolateral (absorptive) from basolateral-to-apical (secretory) flux, aiding in the identification of efflux transporter substrates like those recognized by MDR1. Beyond , Caco-2 cells support investigations into food bioactives, , , and viral infections (e.g., susceptibility to HIV-1 and noroviruses), as well as 3D cultures for more complex tissue modeling. Despite these strengths, limitations include the absence of mucus production, an unstirred water layer, and non-enterocyte cell types, which can overestimate permeability for hydrophilic compounds or underestimate metabolism-dependent absorption; co-cultures with mucus-secreting cells like HT29-MTX are often used to address these gaps. Regulatory bodies such as the FDA and EMA endorse Caco-2 assays as a standard for (BCS) assignments, underscoring their role in drug development workflows.

Origin and Development

Establishment of the Cell Line

The Caco-2 cell line was isolated in 1977 from a heterogeneous colorectal tumor excised from a 72-year-old Caucasian male patient at the Sloan–Kettering Institute for Cancer Research in New York. The isolation was performed by Jorgen Fogh and colleagues using the explant culture technique, in which small pieces of the tumor tissue were directly cultured to allow outgrowth of epithelial cells. This method facilitated the initial establishment of the line without the need for enzymatic dissociation, preserving the heterogeneous nature of the tumor source, which included a mix of poorly differentiated cells. Following isolation, the Caco-2 cells were characterized as an adherent epithelial cell line capable of forming monolayers in standard culture conditions. The line achieved immortality spontaneously through continuous serial passaging, relying on the inherent tumorigenic properties of the source material rather than artificial transformation agents such as viruses or chemical mutagens. No exogenous interventions were required to maintain indefinite proliferation, distinguishing it from finite primary cell cultures. Early post-isolation viability was robust, with the cells demonstrating consistent attachment and expansion in nutrient-rich media. Initial growth kinetics post-establishment showed a doubling time of approximately 20-30 hours, reflecting the proliferative vigor of low-passage cells derived from the aggressive . This rapid early replication supported the line's suitability for long-term maintenance and initial experimental use as a model of colonic . The cell line was subsequently provided to Alain Zweibaum's at INSERM in , where it was further characterized and optimized for research. Subsequent studies by Zweibaum's group further explored its potential for differentiation research.

Historical Milestones

The Caco-2 cell line, derived from a colorectal in 1977, underwent initial characterization in the early that revealed its potential for modeling intestinal epithelial behavior. A landmark study in 1983 by Pinto et al., led by Alain Zweibaum at INSERM in , demonstrated that prolonged culture of Caco-2 cells induces spontaneous enterocyte-like differentiation, including the formation of enzymes and dome structures indicative of polarization, marking the first recognition of its utility in studying intestinal cell maturation. Throughout the , Zweibaum's group at INSERM advanced understanding of Caco-2 differentiation, establishing it as a model for enterocytic functions through serial publications on polarization and expression. Concurrently, researchers Ismael Hidalgo at the and Tom Raub at the Upjohn Company explored its applications in permeability, adapting the cells to permeable supports to mimic intestinal barriers for drug transport studies. The pivotal 1989 publication by Hidalgo, Raub, and Borchardt validated Caco-2 monolayers as a predictive model for intestinal absorption, showing that permeability coefficients for passively transported compounds correlated strongly with in vivo data from models, thereby shifting focus toward pharmaceutical applications. By the , Caco-2 had gained widespread adoption in pharmaceutical screening for drug absorption predictions, with high-throughput assays integrated into early pipelines across industry labs to evaluate compound efficiently. Standardization efforts accelerated in the early , as evidenced by the U.S. FDA's 2000 guidance on biowaivers, which endorsed Caco-2 permeability assays alongside models for supporting bioavailability classifications under the (BCS). In the 2020s, advancements in have enhanced Caco-2's precision, with /Cas9-mediated knockouts of transporters like enabling targeted studies of drug efflux and uptake mechanisms, as demonstrated in models developed for improved absorption predictions. These modifications, including validations in Caco-2 subclones like TC7 for lipoprotein-related investigations, continue to refine the model's relevance for personalized .

Biological Characteristics

Morphology and Differentiation

Caco-2 cells in their undifferentiated state exhibit a characteristic morphology, forming polygonal, tightly packed colonies with epithelial-like adherence to the culture substrate. This appearance reflects their origin as polarized epithelial cells derived from a colorectal , though they initially lack the specialized features of mature enterocytes. Upon reaching , Caco-2 cells undergo spontaneous differentiation, typically over 14–21 days in culture, transitioning into polarized monolayers with distinct apical and basolateral domains. The apical surface develops densely packed microvilli forming a , while the basolateral membrane establishes vectorial polarity, mimicking the organization of . This process follows a mosaic pattern, where subpopulations of cells progressively acquire differentiated traits. As differentiation advances, tight junctions assemble between adjacent cells, evidenced by the expression and localization of zonula occludens-1 (ZO-1), which stabilizes the paracellular barrier and prevents leakage across the monolayer. In fully confluent cultures, these tight junctions contribute to dome formation, where fluid accumulation beneath the monolayer creates hemispherical elevations indicative of functional polarity and transepithelial transport. Ultrastructural analysis via electron microscopy confirms the presence of a well-developed on the apical domain, complete with microvilli rich in filaments, and desmosomes facilitating strong cell-cell . These features closely resemble those of enterocytes, including the glycocalyx-covered microvilli and junctional complexes, despite the cells' colonic derivation. The quality and consistency of differentiation are passage-dependent, with optimal formation and polarization observed between passages 30 and 60, beyond which heterogeneity increases, leading to variable dome formation and reduced barrier integrity.

Molecular and Functional Properties

Differentiated Caco-2 cells express a range of intestinal enzymes that recapitulate key aspects of function, including sucrase-isomaltase for carbohydrate digestion, for phosphate , and dipeptidyl peptidase IV for processing. These enzymes are upregulated during spontaneous differentiation, typically peaking 14-21 days post-confluence, supporting the cells' role as a model for absorptive processes. The cells exhibit polarized expression of transporter proteins essential for nutrient and drug handling, with apical transporters such as PEPT1 facilitating peptide uptake and (MDR1) mediating efflux of xenobiotics back into the lumen. Basolateral transporters, including MRP3, enable secretion toward the bloodstream, contributing to vectorial transport across the monolayer. This asymmetric distribution aligns with the morphological polarization of the cells into enterocyte-like structures. Barrier integrity in differentiated Caco-2 monolayers is quantified by transepithelial electrical resistance (TEER) values typically ranging from 200 to 500 Ω·cm², reflecting robust tight junctions and low paracellular permeability. Metabolically, the cells support Phase I oxidation via enzymes (e.g., , at low levels) and Phase II conjugation through and sulfation pathways, though expression is generally lower than in native human intestine. Genetically, Caco-2 cells display abnormalities, resulting in a modal chromosome number of approximately 96; despite this , the line maintains phenotypic consistency across passages and laboratories, ensuring reproducible functional properties.

Cultivation Methods

Culture Conditions and Protocols

Caco-2 cells are routinely cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10-20% (FBS), 1% non-essential amino acids (NEAA), 1 mM , and antibiotics such as 100 U/mL penicillin and 100 μg/mL . Cultures are maintained at 37°C in a humidified atmosphere of 5% CO₂. This formulation supports robust proliferation while mimicking physiological nutrient conditions. For maintenance, cells are seeded at a density of 1-5 × 10⁴ viable cells/cm² to achieve optimal growth without overcrowding. Subculturing occurs every 3-5 days when cultures reach 70-80% , using 0.25% trypsin-EDTA for detachment followed by neutralization with complete medium. A split ratio of 1:4 to 1:6 is typically employed, with medium renewed 1-2 times per week to prevent nutrient depletion and accumulation of metabolic waste. To minimize phenotypic drift and , Caco-2 cells should be used within passages 20-50, as higher passages can alter and barrier properties. Regular testing is essential, often performed via PCR or indicator methods, to ensure contamination-free stocks. For enhanced differentiation toward enterocytic phenotypes, variations include reducing serum to 2% FBS after initial attachment or supplementing with 1-5 mM during the differentiation period. These adjustments promote polarization without compromising viability, though standard protocols suffice for routine . Viability and health are monitored using exclusion, targeting >90% viable cells prior to subculturing, alongside for uniform morphology and absence of contamination.

Monolayer Formation Techniques

Caco-2 monolayers are typically formed on porous inserts to enable studies of transcellular and paracellular transport across a polarized epithelial barrier. These inserts, such as Transwell or Snapwell systems, feature or membranes with pore sizes ranging from 0.4 to 3 μm, which allow nutrient diffusion while preventing and supporting bidirectional access to apical and basolateral compartments for transport assays. Cells are seeded at densities of 5 × 10⁴ to 1 × 10⁵ per insert onto these supports, followed by a culture period of 14-21 days to achieve full differentiation into a confluent with tight junctions and enzymes. During this time, transepithelial electrical resistance (TEER) stabilizes as an indicator of barrier integrity. To enhance physiological relevance, co-cultures integrate mucus-producing HT29-MTX cells at ratios of 10-20% with Caco-2 cells, forming a heterogeneous that secretes a layer mimicking the intestinal environment. Monolayer integrity is validated using permeability assays with paracellular markers: apparent permeability (P_app) for yellow should be below 1 × 10^{-6} cm/s to confirm low leakage, while serves as a standard probe for functionality. Commercial kits like CacoReady provide pre-differentiated Caco-2 monolayers on inserts, shipped at day 13 of culture for immediate use up to day 21, thereby minimizing inter-laboratory variability in differentiation and barrier formation.

Research Applications

Drug Permeability and Absorption Studies

Caco-2 monolayers serve as a primary model for evaluating drug permeability across the , enabling predictions of oral early in pharmaceutical development. These cells form polarized barriers mimicking the human , allowing assessment of passive diffusion and mechanisms. Permeability studies typically involve measuring the of test compounds across the under controlled conditions, with results providing insights into absorption potential. Bidirectional transport assays are routinely employed to distinguish between absorptive and secretory pathways, particularly to identify substrates of efflux transporters like (). In these experiments, drug flux is quantified from the apical-to-basolateral (A-B) direction, simulating intestinal absorption, and from the basolateral-to-apical (B-A) direction, indicating potential efflux. The efflux ratio, calculated as the B-A permeability divided by A-B permeability, helps classify compounds; ratios greater than 2 typically suggest -mediated efflux, guiding further investigation into drug-transporter interactions. The apparent permeability coefficient (P_app) is the key metric derived from these assays, providing a standardized measure of transport efficiency. It is computed using the formula: Papp=dQ/dtA×C0P_{app} = \frac{dQ/dt}{A \times C_0} where dQ/dtdQ/dt represents the steady-state flux rate (amount per unit time), AA is the surface area of the , and C0C_0 is the initial donor concentration. This calculation assumes sink conditions on the receiver side and is performed after verifying monolayer integrity via transepithelial electrical resistance (TEER). Caco-2-derived P_app values correlate strongly with in vivo human intestinal absorption, with high permeability (P_app > 10^{-5} cm/s) predicting greater than 90% absorption for many compounds. This relationship has been validated against the Biopharmaceutics Drug Disposition Classification System (BDDCS), where high permeability aligns with extensive metabolism and distribution, aiding in the classification of drugs into BDDCS Classes 1 and 2. Such correlations support the model's reliability for forecasting without relying solely on animal data. In pharmaceutical screening, Caco-2 assays are integral to (BCS) evaluations, categorizing compounds based on solubility and permeability to inform formulation strategies and biowaiver applications. For instance, high P_app values confirm BCS Class 1 or 3 status for immediate-release products, streamlining regulatory approvals. Similarly, for peptide-based therapeutics, such as insulin analogs, the model assesses paracellular and transcellular routes, highlighting low permeability challenges for oral delivery of biologics. Post-2018 advancements have enhanced Caco-2's predictive accuracy, including hybrid models combining Caco-2 with MDCK cells for refined transporter studies and integration of for machine learning-based permeability predictions. These AI approaches, trained on large datasets, achieve up to 90% accuracy in classifying permeability classes, reducing experimental variability and accelerating as of 2025. Microfluidic adaptations further mimic dynamic intestinal flow, improving correlations with in vivo absorption.

Toxicity and Other Biomedical Uses

Caco-2 cells are widely employed in cytotoxicity assays to evaluate the toxic potential of various compounds, leveraging their ability to form differentiated monolayers that mimic intestinal epithelial barriers. Common methods include the , which measures mitochondrial dehydrogenase activity to assess cell viability, and the LDH release assay, which detects leakage as an indicator of plasma membrane damage. For instance, in studies of phycotoxins, the LDH assay demonstrated higher sensitivity in detecting in Caco-2 cells compared to Alamar Blue, with values varying by toxin type and exposure duration. Similarly, nanotoxicology research has utilized these assays to investigate uptake and effects; colloidal silver nanoparticles exhibited dose- and time-dependent in Caco-2 cells, with significant viability reduction at concentrations as low as 5 μg/mL after 48 hours, attributed to and membrane disruption. In models, Caco-2 monolayers serve as a platform to study and host responses, particularly for enteric like . Polarized Caco-2 cells infected apically with Salmonella typhimurium reveal bacterial adhesion and mechanisms. These models have quantified rates, modulated by host factors such as C signaling, which reduces . For viral s, Caco-2 cells support replication cycles of pathogens like virus genotype 1, achieving efficient and propagation, enabling studies on viral entry and maturation without significant at low multiplicities of . Caco-2 cells model transport processes, including and absorption, due to their expression of relevant transporters and receptors. In studies, Caco-2 monolayers facilitate the uptake of fatty acids like , with co-culture systems enhancing transport efficiency by simulating adipose interactions. transport assays have shown that lipidated peptides, such as those with varying chain lengths, undergo endocytosis-mediated translocation, with longer chains significantly increasing absorption rates across the monolayer. Regarding , Caco-2 cells express the (VDR), and treatment with 1,25-dihydroxyvitamin D3 upregulates VDR-mediated uptake of associated nutrients; for example, it enhances folic acid transport via increased expression of receptors, while glycocholic acid and butyrate synergistically boost calcium absorption up to 9-fold through VDR activation. As a model for , Caco-2 cells are used to investigate and resistance, reflecting their origin from a colon . In studies, Caco-2 variants derived from serial exhibit enhanced invasive potential, with ROCK2 inhibition promoting collective and stromal invasion in 3D models. For resistance, Caco-2 cells overexpressing genes like RBCK1 or TIAM1 display reduced sensitivity to agents such as due to stemness activation and anoikis resistance linked to mutations. Emerging applications in the 2020s integrate Caco-2 cells into platforms to study gut interactions, providing dynamic models of host-microbe dynamics. These microfluidic systems co-culture Caco-2 monolayers with anaerobic bacteria, simulating and revealing influences on barrier integrity, such as reduced invasion by in the presence of protective postbiotics from . Such models have demonstrated that microbial metabolites modulate Caco-2 responses, enhancing research into dysbiosis-related toxicity and nutrient modulation in a physiologically relevant context.

Advantages, Limitations, and Comparisons

Strengths and Validation

The Caco-2 cell model offers significant high-throughput capabilities, enabling the cost-effective screening of thousands of drug compounds annually through automated protocols and scalable multi-well formats. This efficiency stems from optimized cultivation and permeability assays that reduce time and resource demands compared to traditional methods, facilitating early-stage in pharmaceutical pipelines. Regulatory agencies, including the FDA and EMA, endorse the Caco-2 model for biowaiver applications under the (BCS), allowing waiver of bioavailability studies when apparent permeability (P_app) values demonstrate strong correlation with human jejunal data for passively transported compounds. This acceptance is supported by extensive validation showing reliable prediction of intestinal absorption, as outlined in ICH M9 guidelines. Ethically, the Caco-2 model adheres to the 3Rs principle—replacement, reduction, and refinement—by serving as a human-relevant alternative to , while maintaining a consistent epithelial across laboratories worldwide. This reduces reliance on models and promotes reproducible results without ethical concerns associated with animal use. Quantitative validations confirm the model's robustness, with studies reporting 80-90% accuracy in predicting absorption for passively diffused drugs, based on correlations between Caco-2 permeability and clinical data.

Drawbacks and Variability Issues

The Caco-2 cell line, derived from colorectal , exhibits incomplete mimicry of the , as it overexpresses certain colonic markers such as MUC2 and underrepresents key -specific transporters like organic anion-transporting polypeptides (OATPs), including OATP1A2 and OATP2B1, which are crucial for uptake of endogenous compounds and drugs. This colonic bias limits its accuracy in modeling jejunal or ileal absorption, where OATP expression is higher, leading to potential underestimation of transporter-mediated influx in permeability studies. Passage-dependent effects contribute significantly to variability, with occurring after approximately passage 60, resulting in altered morphology, reduced activities like , and variability in apparent permeability coefficients (P_app) for test compounds due to inconsistent monolayer integrity. Transepithelial electrical resistance (TEER) values, a marker of , peak around passages 30-50 but decline thereafter, exacerbating inconsistencies in measurements across experiments. Inter-laboratory differences further amplify variability, with TEER measurements fluctuating due to variations in media composition, lots, and seeding densities (typically 10^5 to 5x10^5 cells/cm²), yielding coefficients of variation (CV) up to 30% in permeability assays. These discrepancies arise from heterogeneous cell subpopulations and non-standardized protocols, making direct comparisons of P_app values challenging and reducing reproducibility across studies. Metabolic limitations are prominent, as Caco-2 cells display substantially lower activity—responsible for metabolizing about 50% of drugs—compared to native human enterocytes, often requiring induction agents like 1α,25-dihydroxyvitamin D3 for even modest expression. This reduced enzymatic capacity hinders accurate prediction of activation and first-pass metabolism, potentially overestimating for substrates in absorption studies. Recent critiques, particularly in 2024-2025 literature, highlight overreliance on Caco-2 data in AI-driven models, where historical data gaps and biases amplify errors, such as in permeability , due to underrepresented chemical spaces and inherent experimental variability. This perpetuates flawed extrapolations, underscoring the need for cautious integration of Caco-2-derived datasets in pipelines for ADMET forecasting.

Alternatives to Caco-2 Models

Madin-Darby canine kidney (MDCK) cells serve as a common alternative to Caco-2 models for assessing intestinal drug permeability, particularly in scenarios. These cells differentiate more rapidly, forming tight monolayers in 3-5 days compared to the 21 days typically required for Caco-2, enabling faster experimental turnaround. MDCK cells, especially the MDCK-MDR1 variant overexpressing , excel in evaluating efflux transporter activity, often providing permeability rankings that correlate well with Caco-2 for passively transported compounds. However, their canine origin limits relevance, as they exhibit differences in transporter expression and may overestimate permeability for some substrates due to lower paracellular leakage. Co-cultures of Caco-2 with HT29 cells, particularly the mucus-secreting HT29-MTX subline, enhance model realism by incorporating a physiological layer absent in standard Caco-2 monolayers. In typical 70:30 Caco-2:HT29 ratios, these systems better mimic the intestinal barrier's heterogeneity, with HT29 cells representing goblet cells that produce and influence drug diffusion. Such co-cultures demonstrate improved prediction of and interactions at the mucosal surface, though they increase experimental complexity due to variable thickness and longer differentiation times. Permeability measurements in these models often align with Caco-2 for small molecules but provide more accurate barriers for mucoadhesive compounds. Induced pluripotent stem cell (iPSC)-derived enteroids offer a patient-specific, three-dimensional alternative that recapitulates the crypt-villus architecture and cellular diversity of human intestine, surpassing Caco-2's limitations. These organoid-derived monolayers express a broader range of transporters and metabolic enzymes, yielding permeability correlations with in vivo human data that are comparable or superior to Caco-2 for both passive and . For instance, iPSC-enteroids better predict regional differences in absorption along the and . Despite their higher fidelity to native tissue, challenges include high production costs, variability from donor , and technical demands for 3D-to-2D adaptation in permeability assays. Ussing chambers mounted with ex vivo animal intestinal tissues, such as porcine or rat jejunum, represent a gold standard for validating permeability models due to their retention of native architecture, including multiple cell types and innervation. These setups measure transepithelial electrical resistance and flux under physiological conditions, often providing more accurate predictions of drug absorption than Caco-2 for ion-sensitive or poorly soluble compounds. However, ethical concerns over animal use, short tissue viability (typically 1-3 hours), and inter-animal variability restrict their routine application, positioning them primarily as confirmatory tools rather than scalable alternatives. Computational models, including physiologically based pharmacokinetic (PBPK) simulations and quantitative structure-activity relationship (QSAR) approaches, emerge as cell-free alternatives for predicting drug absorption without relying solely on Caco-2 data. PBPK models integrate Caco-2 permeability inputs with in silico estimates of and to simulate whole-body , achieving high accuracy for BCS class I-III drugs in regulatory submissions. Recent 2025 advancements in QSAR leverage on large datasets to forecast permeability directly from molecular descriptors, reducing experimental needs and enabling early-stage screening. These tools are particularly preferable for virtual prototyping but require validation against empirical data to account for transporter interactions.

References

  1. https://www.atcc.org/products/htb-37
  2. https://www.culturecollections.org.uk/products/cell-cultures/ecacc-cell-line-profiles/caco-2/
  3. https://www.ncbi.nlm.nih.gov/books/NBK500149/
  4. https://pubmed.ncbi.nlm.nih.gov/15868485/
  5. https://pubmed.ncbi.nlm.nih.gov/9282267/
  6. https://pubmed.ncbi.nlm.nih.gov/29787057/
  7. https://pubmed.ncbi.nlm.nih.gov/1673839/
  8. https://pubmed.ncbi.nlm.nih.gov/16922635/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC9123034/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC9304606/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC10674574/
  12. https://pubmed.ncbi.nlm.nih.gov/38004503/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC4830044/
  14. https://www.researchgate.net/publication/347060607_Differentiated_Caco-2_cell_models_in_food-intestine_interaction_study_Current_applications_and_future_trends
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC3160153/
  16. https://pubmed.ncbi.nlm.nih.gov/2914637/
  17. https://www.sciencedirect.com/topics/medicine-and-dentistry/caco-2-cell-line
  18. https://www.govinfo.gov/app/details/FR-2000-08-31/00-22225
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC9649518/
  20. https://www.mdpi.com/2072-6643/15/3/505
  21. https://www.researchgate.net/publication/51477141_GM1_Expression_in_Caco-2_Cells_Characterisation_of_a_Fundamental_Passage-dependent_Transformation_of_a_Cell_Line
  22. https://journals.biologists.com/jcs/article/102/3/581/23382/Characterization-of-the-enterocyte-like-brush
  23. https://pubmed.ncbi.nlm.nih.gov/1634060/
  24. https://pubmed.ncbi.nlm.nih.gov/20345370/
  25. https://pubmed.ncbi.nlm.nih.gov/3161570/
  26. https://www.jbclinpharm.org/articles/caco2-cell-lines-in-drug-discovery-an-updated-perspective.html
  27. https://journals.biologists.com/jcs/article/107/1/213/23894/Differential-expression-of-sucrase-isomaltase-in-Caco-2-cells
  28. https://www.sciencedirect.com/science/article/pii/S0021925818429067
  29. https://www.mdpi.com/1422-0067/24/4/3595
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC9398928/
  31. https://www.sciencedirect.com/science/article/abs/pii/S0090955624100906
  32. https://www.researchgate.net/publication/5812335_Analysis_of_drug_transporter_expression_in_human_intestinal_Caco-2_cells_by_real-time_PCR
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC6487070/
  34. https://core.ac.uk/download/pdf/14914645.pdf
  35. https://www.cellosaurus.org/CVCL_0025
  36. https://journal.pan.olsztyn.pl/pdf-98560-30366
  37. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0245348
  38. https://www.corning.com/catalog/cls/documents/selection-guides/CLS-CC-027.pdf
  39. https://currentprotocols.onlinelibrary.wiley.com/doi/10.1002/0471140856.tx2006s47
  40. https://pubs.acs.org/doi/10.1021/acsomega.9b00496
  41. https://biologicalproceduresonline.biomedcentral.com/articles/10.1186/s12575-020-00120-w
  42. https://www.sciencedirect.com/science/article/pii/S2405580822001145
  43. https://pubmed.ncbi.nlm.nih.gov/20159047/
  44. https://www.mdpi.com/1999-4923/13/10/1563
  45. https://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.9b00733
  46. https://f.hubspotusercontent20.net/hub/108420/file-17387373.pdf/cacoready_technical_note.pdf
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC4355448/
  48. https://www.sciencedirect.com/science/article/pii/S2590156724000410
  49. https://bienta.net/caco-2-assay/caco-2-validation/
  50. https://www.evotec.com/solutions/drug-discovery-preclinical-development/cyprotex-adme-tox-solutions/adme-pk/drug-permeability-and-transporters/caco-2-permeability
  51. https://www.sciencedirect.com/science/article/abs/pii/S0169409X12002657
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC3580995/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC5415745/
  54. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057136
  55. https://www.tandfonline.com/doi/full/10.1080/1062936X.2025.2552134
  56. https://www.sciencedirect.com/science/article/abs/pii/S0378517322005592
  57. https://www.sciencedirect.com/science/article/pii/S0147651322012878
  58. https://www.sciencedirect.com/science/article/pii/S2405844020314389
  59. https://pubmed.ncbi.nlm.nih.gov/29367634/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC11261143/
  61. https://www.sciencedirect.com/science/article/pii/S0168365923000755
  62. https://pubmed.ncbi.nlm.nih.gov/19666701/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC7371747/
  64. https://www.sciencedirect.com/science/article/pii/S0753332219319754
  65. https://www.nature.com/articles/s41419-019-1493-5
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC9977465/
  67. https://www.mdpi.com/2076-2615/13/20/3215
  68. https://pubmed.ncbi.nlm.nih.gov/12955746/
  69. https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/388/213/an1727en00.pdf
  70. https://www.fda.gov/media/148472/download
  71. https://www.ema.europa.eu/en/documents/other/ich-m9-biopharmaceutics-classification-system-based-biowaivers-step-5-questions-and-answers_en.pdf
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC8622701/
  73. https://www.sciencedirect.com/science/article/pii/0006291X9191647U
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC3372714/
  75. https://pubmed.ncbi.nlm.nih.gov/28408210/
  76. https://pubmed.ncbi.nlm.nih.gov/9083258/
  77. https://www.ebm-journal.org/journals/experimental-biology-and-medicine/articles/10.3181/00379727-214-44093/pdf
  78. https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c00108
  79. https://pubmed.ncbi.nlm.nih.gov/9145912/
  80. https://www.mdpi.com/1999-4923/12/5/405
  81. https://pubs.acs.org/doi/10.1021/acs.jcim.4c01083
  82. https://jcheminf.biomedcentral.com/articles/10.1186/s13321-025-00947-z
  83. https://dda.creative-bioarray.com/cell-based-intestinal-permeability-models.html
  84. https://www.sciencedirect.com/science/article/abs/pii/S1056871914002433
  85. https://pubmed.ncbi.nlm.nih.gov/25150934/
  86. https://www.ncbi.nlm.nih.gov/books/NBK500138/
  87. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257824
  88. https://portlandpress.com/bioscirep/article/38/2/BSR20171497/57179/Morphofunctional-properties-of-a-differentiated
  89. https://www.nature.com/articles/s41598-024-74802-w
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC3703544/
  91. https://www.sciencedirect.com/science/article/pii/S0928098724001891
  92. https://pubmed.ncbi.nlm.nih.gov/37711012/
  93. https://www.mdpi.com/1999-4923/11/3/139
  94. https://link.springer.com/article/10.1007/s11095-024-03725-y
  95. https://www.tandfonline.com/doi/full/10.1080/1062936X.2025.2478118
  96. https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.2c00040
Add your contribution
Related Hubs
User Avatar
No comments yet.